Lexicon (LXRX) delivered earnings and revenue surprises of -11.11% and 3.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Exploring the Financial and Operational Milestones of Lexicon Pharmaceuticals in the First Quarter of 2024
Commercial launch of INPEFA® (sotagliflozin) for Heart Failure continues to progress Resubmission of NDA for ZYNQUISTA™ (sotagliflozin) in Type 1 Diabetes expected mid-year 2024 Start-up ongoing for Phase 3 study of sotagliflozin in Hypertrophic Cardiomyopathy, with enrollment expected to begin mid-year 2024 Enrollment in Phase 2b PROGRESS study of LX9211 in Diabetic Peripheral Neuropathic Pain on track for expected Q2 2025 topline data Conference Call and Webcast at 5:00 pm Eastern Time THE WOO